Synaptech

Synaptech Inc. was a California-based biotechnology company focused on the development of therapies for Alzheimer's disease and other neurodegenerative disorders. Founded by prominent researchers in the field of neurobiology, the company played a pivotal role in the clinical development and licensing of key Alzheimer's medications, including memantine and galantamine. Synaptech's business model involved identifying promising neuroprotective compounds and advancing them through regulatory pathways. The company was acquired by Forest Laboratories in 2000, which subsequently commercialized memantine as Namenda in the United States. This acquisition was a significant event in the consolidation of Alzheimer's research and development during that period.